期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

利用艾司奥美拉唑调整伏立康唑血药浓度治疗曲霉菌感染的案例分析 被引量：1

Clinical Pharmacists Participated in a Case Used Drug Interactions of Esomeprazole to Adjust the Plasma Concentration of Voriconazole for the Treatment of Aspergillosis:A Case Analysis
下载PDF
导出
摘要 临床药师参与1例罕见的CYP2C19快代谢型患者使用伏立康唑治疗侵袭性曲霉菌感染的救治,对治疗过程中患者伏立康唑血药浓度过低的原因进行分析,并利用艾司奥美拉唑调整伏立康唑的血药浓度,促进临床合理使用抗菌药物。本案例为临床治疗难治性肺曲霉病提供了参考。 Clinical pharmacists participated in the treatment of a rare CYP2 C19 fast-metabolizing patient who was treated with voriconazole for invasive aspergillosis infection,and analyzed the reasons for the excessively low blood concentration of voriconazole in the treatment process of this patient,and adjusted the blood concentration of voriconazole with esomeprazole.It provides reference for the clinical treatment of refractory pulmonary aspergillosis and promotes the rational use of antibiotics in clinical practice.
作者 罗梦林 蔡小利 叶飞 Luo Menglin;Cai Xiaoli;Ye Fei(Department of Pharmacy,The Second Affiliated Hospital of The Army Medical University,Chongqing 400037,China)
机构地区 陆军军医大学第二附属医院医院药剂科
出处 《药物流行病学杂志》 CAS 2021年第6期408-410,共3页 Chinese Journal of Pharmacoepidemiology
基金 陆军军医大学科技创新能力提升专项项目(编号:2019XLC3023)。
关键词 临床药师 伏立康唑 艾司奥美拉唑 曲霉菌 药物相互作用 药学监护 Clinical pharmacists Voriconazole Esomeprazole Aspergillus Drug interactions Pharmaceutical care
分类号 R97 [医药卫生—药品]
  • 相关文献

参考文献1

二级参考文献13

  • 1JEU LtPIACENTI F J,LYAKHOVETSKIY A G,et al.Voriconazole[J].Clin Ther,2003,25(5):1321-1381.
  • 2PESTKA E L,HALE A M,JOHNSON B L,et al.Cytochrome P450 testing for better psychiatric care[J].J Psychosoc Nurs Ment Health Serv,2007,45(10):15-18.
  • 3HOZO S P,DJULBEGOVIC B,HOZO I.Estimating the mean and variance from the median,range,and the size of a sample[J].BMC Med Res MeiWoZ,2005,5(13):5-13.
  • 4LEE S.Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers[J].J Clin Pharrtmcol,2012,52(2):195-203.
  • 5LEI H P,WANG G,WANG L S,et al.Lack of effect of Ginkgo bi- loba on voriconazole pharmacokinetics in Chinese volunteers identi- fied as CYP2C19 poor and extensive metabolizers[J].Ann Phar- macother,2009,43(4):726-731.
  • 6MIKUS G,SCHOWEL V,DRZEWINSKA M,et al.Potent cyto- chrome P4502C19 genotype-related interaction between vori- conazole and the cytochrome P4503A4 inhibitor ritonavir[J].Clin Pharmacol Ther,2006,80(2):126-135.
  • 7RENGELSHAUSEN J,BANFIELD M,RIEDEL K D,et al.Oppo- site effects of short-term and long-term St John wort intake on voriconazole pharmacokinetics[J].Clin Pharmacol TTter,2005,78(1):25-33.
  • 8WANG G,LEI H P,LI Z,et al.The CYP2C19 ultra-rapid meta- I.(bolizer genotype influences the pharmacokinetics of voriconazole in heaithy male volunteers[J].Eur J Clin Pharmacol,2009,65(3):281-285.
  • 9WEISS J,TEN H M M,BURHENNE J,et al.CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole[J].J Clin Pharmacol,2009,49(2):196-204.
  • 10SCHOLZ I,OBERWITTLER HjRIEDEL K D,et al.Pharmacoki- netics,metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype[J].Br J Clin Phar- rrmcol,2009f6S(6):906-915.

共引文献6

同被引文献27

引证文献1

药物流行病学杂志
2021年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部